CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog designed to stimulate natural GH production from the pituitary gland with significantly extended duration of action. CJC-1295 is a modified version of GHRH (1-29) featuring: - 4 amino acid substitutions at key positions (D-Ala², Gln⁸, Ala¹⁵, Leu²⁷) - 29-30 amino acids depending on DAC addition - Improved resistance to enzymatic breakdown (dipeptidyl peptidase-4) - Half-life: 30-60 minutes - Dosing: Multiple times per day in research protocols - GH Pattern: Pulsatile, mimics natural physiological release - Also Known As: Mod GRF (1-29) - Half-life: 6-8 days (up to 10 days reported) - Dosing: Once weekly in research protocols - Mechanism: DAC component binds to serum albumin, preventing degradation - GH Pattern: Sustained elevation over days - Binds to GHRH receptors on somatotroph cells in the anterior pituitary - Stimulates pulsatile GH release - Increases downstream IGF-1 production in the liver - Mimi
CJC-1295: GHRH Analog Research Guide
Exploring CJC-1295, the modified growth hormone-releasing hormone analog with extended half-life properties.